Patient engagement in research : lessons learned from CAPTURE ALS, a longitudinal observational ALS study
Objective: There are compelling ethical and practical reasons for patient engagement in research (PEIR), however, evidence for best practices remains limited. We investigated PEIR as implemented in CAPTURE ALS, a longitudinal observational study, from study inception through the first 2.5 years of operations. Methods: Data were drawn from three engagement initiatives: a community-led letter-writing campaign; consultation with patient and caregiver focus groups; and a study-embedded 'participant partner advisory council' (PPAC). Data were derived retrospectively from study documentation. We used the International Association of Public Participation (IAP2) participation spectrum as a framework for investigation. Results: 2401 letters from community members to the Canadian government affirmed study objectives and advocated for funding. Feedback from focus group consultation influenced study design and supported the study's data-sharing plan. PPAC collaboration shaped all aspects of the study. Contributions included: co-creation of governance documents, input on study protocols and public-facing communication, and development of engagement webinars for study participants and feedback surveys. Effective communication practices fostered collaboration and helped avoid tokenistic engagement. CAPTURE ALS encompassed all IAP2 participation levels. Conclusions: CAPTURE ALS was shaped by meaningful engagement initiatives over the course of the study. Lessons learned included: begin early and embed PEIR within research; build relationships and foster mutual learning; be flexible, open to adaptation, and seek diversity. Primary challenges included funding for early implementation, time needed to maintain relationships, and attrition due to disease progression. All IAP2 participation levels contributed to meaningful PEIR. 'Empowerment' was demonstrated through advocacy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Amyotrophic lateral sclerosis & frontotemporal degeneration - (2024) vom: 22. März, Seite 1-10 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Genuis, Shelagh K [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Advisory committees |
|---|
| Anmerkungen: |
Date Revised 23.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1080/21678421.2024.2328599 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370094417 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370094417 | ||
| 003 | DE-627 | ||
| 005 | 20240324235315.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240324s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/21678421.2024.2328599 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1345.xml |
| 035 | |a (DE-627)NLM370094417 | ||
| 035 | |a (NLM)38519870 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Genuis, Shelagh K |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Patient engagement in research |b lessons learned from CAPTURE ALS, a longitudinal observational ALS study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 23.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Objective: There are compelling ethical and practical reasons for patient engagement in research (PEIR), however, evidence for best practices remains limited. We investigated PEIR as implemented in CAPTURE ALS, a longitudinal observational study, from study inception through the first 2.5 years of operations. Methods: Data were drawn from three engagement initiatives: a community-led letter-writing campaign; consultation with patient and caregiver focus groups; and a study-embedded 'participant partner advisory council' (PPAC). Data were derived retrospectively from study documentation. We used the International Association of Public Participation (IAP2) participation spectrum as a framework for investigation. Results: 2401 letters from community members to the Canadian government affirmed study objectives and advocated for funding. Feedback from focus group consultation influenced study design and supported the study's data-sharing plan. PPAC collaboration shaped all aspects of the study. Contributions included: co-creation of governance documents, input on study protocols and public-facing communication, and development of engagement webinars for study participants and feedback surveys. Effective communication practices fostered collaboration and helped avoid tokenistic engagement. CAPTURE ALS encompassed all IAP2 participation levels. Conclusions: CAPTURE ALS was shaped by meaningful engagement initiatives over the course of the study. Lessons learned included: begin early and embed PEIR within research; build relationships and foster mutual learning; be flexible, open to adaptation, and seek diversity. Primary challenges included funding for early implementation, time needed to maintain relationships, and attrition due to disease progression. All IAP2 participation levels contributed to meaningful PEIR. 'Empowerment' was demonstrated through advocacy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Advisory committees | |
| 650 | 4 | |a amyotrophic lateral sclerosis (ALS) | |
| 650 | 4 | |a patient and public involvement | |
| 650 | 4 | |a patient engagement in research | |
| 650 | 4 | |a research design | |
| 700 | 1 | |a Luth, Westerly |e verfasserin |4 aut | |
| 700 | 1 | |a Magnussen, Claire |e verfasserin |4 aut | |
| 700 | 1 | |a Vande Velde, Christine |e verfasserin |4 aut | |
| 700 | 1 | |a Taylor, David |e verfasserin |4 aut | |
| 700 | 0 | |a CAPTURE ALS Participant Partner Advisory Council |e verfasserin |4 aut | |
| 700 | 1 | |a Johnston, Wendy S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Amyotrophic lateral sclerosis & frontotemporal degeneration |d 2013 |g (2024) vom: 22. März, Seite 1-10 |w (DE-627)NLM218160313 |x 2167-9223 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:22 |g month:03 |g pages:1-10 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/21678421.2024.2328599 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 22 |c 03 |h 1-10 | ||